The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Aptitude Medical Systems’ Metrix Covid/Flu multiplex test for over-the-counter (OTC) use.
The decision makes the test accessible for at-home testing and in Clinical Laboratory Improvement Amendments (CLIA)-waived point-of-care setting.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This test can reportedly concurrently identify and differentiate influenzas A or B, as well as SARS-CoV-2 in 20 minutes.
In partnership with Sekisui Diagnostics, the company and its distribution partners have made the test available across the US.
According to Aptitude, the development of the Metrix Covid/Flu test has been partially funded by the Department of Health and Human Services, Biomedical Advanced Research and Development Authority; Administration for Strategic Preparedness and Response, under contract number 75A50123C00013.
It is the second molecular test on the platform to receive FDA authorisation, following the Metrix Covid-19 Test, which can be used without professional supervision for at-home use with saliva or swab samples.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAptitude Medical Systems CEO Scott Ferguson said: “We built Metrix to dramatically expand the reach of molecular diagnostics by breaking cost and accessibility barriers.
“Our Metrix Covid/Flu test empowers individuals to get their own lab-quality results on the spot in their homes and enables healthcare providers to upgrade from existing molecular and antigen testing platforms while lowering total cost of care.”
A “deep-tech” healthcare company, Aptitude is focused on detecting and treating infectious diseases.
Last month, the company secured a grant of more than $10m from the Bill & Melinda Gates Foundation.
This funding aims to expedite the development and release of new point-of-care and OTC tests for sexually transmitted infections on the Metrix diagnostics platform, including chlamydia, gonorrhoea, and trichomoniasis.
In April 2023, the company obtained a grant of up to $53.7m from the Biomedical Advanced Research and Development Authority (BARDA) for the development of OTC molecular diagnostic tests.
